Ocular Therapeutix (OCUL) Expected to Announce Quarterly Earnings on Monday

Ocular Therapeutix (NASDAQ:OCUL) is expected to be posting its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect Ocular Therapeutix to post earnings of ($0.33) per share and revenue of $16.1280 million for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 5, 2026 at 7:00 AM ET.

Ocular Therapeutix (NASDAQ:OCUL) last released its earnings results on Thursday, February 5th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.04. The business had revenue of $13.25 million for the quarter, compared to analyst estimates of $16.13 million. Ocular Therapeutix had a negative return on equity of 70.68% and a negative net margin of 511.90%.Ocular Therapeutix’s revenue was down 22.4% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.29) earnings per share. On average, analysts expect Ocular Therapeutix to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Ocular Therapeutix Stock Up 10.7%

OCUL stock opened at $7.78 on Monday. The company has a quick ratio of 15.32, a current ratio of 15.39 and a debt-to-equity ratio of 0.11. The business has a 50 day moving average price of $10.76 and a two-hundred day moving average price of $11.67. The company has a market cap of $1.69 billion, a price-to-earnings ratio of -5.40 and a beta of 0.90. Ocular Therapeutix has a twelve month low of $5.78 and a twelve month high of $16.44.

Insider Transactions at Ocular Therapeutix

In other news, insider Pravin Dugel sold 124,882 shares of the stock in a transaction that occurred on Thursday, February 12th. The stock was sold at an average price of $9.04, for a total transaction of $1,128,933.28. Following the transaction, the insider owned 3,033,078 shares in the company, valued at approximately $27,419,025.12. This trade represents a 3.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Sanjay Nayak sold 10,348 shares of Ocular Therapeutix stock in a transaction that occurred on Thursday, February 12th. The stock was sold at an average price of $9.04, for a total value of $93,545.92. Following the sale, the insider directly owned 332,412 shares of the company’s stock, valued at approximately $3,005,004.48. The trade was a 3.02% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 166,029 shares of company stock worth $1,498,430 over the last three months. Company insiders own 2.30% of the company’s stock.

Hedge Funds Weigh In On Ocular Therapeutix

Institutional investors and hedge funds have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Ocular Therapeutix by 5.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 93,619 shares of the biopharmaceutical company’s stock worth $686,000 after acquiring an additional 5,156 shares during the period. Caxton Associates LLP bought a new position in shares of Ocular Therapeutix during the first quarter worth approximately $248,000. Creative Planning raised its position in shares of Ocular Therapeutix by 21.5% in the second quarter. Creative Planning now owns 21,410 shares of the biopharmaceutical company’s stock valued at $199,000 after buying an additional 3,791 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Ocular Therapeutix by 110.8% in the second quarter. JPMorgan Chase & Co. now owns 712,100 shares of the biopharmaceutical company’s stock valued at $6,608,000 after buying an additional 374,269 shares during the period. Finally, Prudential Financial Inc. boosted its stake in shares of Ocular Therapeutix by 57.9% in the second quarter. Prudential Financial Inc. now owns 18,700 shares of the biopharmaceutical company’s stock valued at $174,000 after buying an additional 6,855 shares during the period. 59.21% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Royal Bank Of Canada reissued an “outperform” rating and issued a $30.00 target price on shares of Ocular Therapeutix in a research note on Thursday, February 5th. Jefferies Financial Group reiterated a “buy” rating on shares of Ocular Therapeutix in a research note on Tuesday, February 17th. Chardan Capital restated a “buy” rating and set a $21.00 price objective on shares of Ocular Therapeutix in a research note on Wednesday, February 18th. Wall Street Zen raised shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a report on Saturday, February 7th. Finally, Citigroup reiterated an “outperform” rating on shares of Ocular Therapeutix in a research note on Tuesday, February 17th. Twelve investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $23.78.

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.